Clinical trial
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00004260 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00004260 |
|---|---|
| Title | Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | Phase I Study of Interleukin-12 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | recombinant interleukin-12, rituximab |
| Start date | Oct 1, 1999 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Jun 18, 2004 |
| Last update posted | Aug 3, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: